| PeterB 2005-09-26, 5:22 pm |
|
Rich wrote:
> "PeterB" <pkm@mytrashmail.com> wrote in message
> news:1127579280.621893.224010@g14g2000cwa.googlegroups.com...
>
> Perhaps YOU don't know how well they work. The rest of us have a pretty good
> idea. Titres are an excellent marker for immunity, by the way. When
> vaccination doesn't "work" it's because it didn't stimulate the body to
> produce the antibodies, not because the antibodies didn't do their job.
I'm glad you have a pretty good idea, however an anti-body titre isn't
equivalent to immunization any more than reduction of a marker for
disease is equivalent to its cure.
>
> There you go again, perpetrating the myth of huge vaccine profits and
> marketing. ALL of the "global" market for vaccines represents less than the
> market for the impotence meds alone. A Viagra pill is a lot cheaper to
> produce and has a higher markup by far than an MMR shot.
See comments above on subsidy support for vaccine.
> As for flu vaccines, "stock-piling" does not make sense for a vaccine that
> is defferent every year to keep up with the variation in the world's
> predominant strains. The distribution issues can get tricky when, like last
> year, there is a rare vaccine shortage due to a manufacturing glitch.
> Distribution is also going to be a problem when a vaccine is developed for
> the avian flu virus, because the pandemic may be well underway before the
> morhpology of the virus is determined and the vaccine is in full production.
> But those are issues about how to protect the most people from the disease,
> not how to protect the profits of the pharm companies.
Financial issues are always a primary driver in corporate decision
making.
PeterB
|